Skip to main content
Caplight Logo









iProtics

iProtics

Private
LeidenHealthcare & Life Scienceshttps://iprotics.eu/

Last Round

Seed

Oct 10, 2024

Total Funding Raised

$850,000

Company Overview

iProtics is a biotechnology company developing selective immunoproteasome inhibitors to treat hematological cancers and autoimmune disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immunoproteasome inhibitorpeptide-based therapydrug discoveryhematological cancerautoimmune disorderbiotech startuppre-clinical developmenttargeted therapyoncology researchbiotech spin-outproteasome inhibitorprecision medicinedrug pipelinebiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

iProtics Comparables

Compare iProtics with similar companies based on industry and business-model similarity.

iProtics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
IpiNovyx Bio
87%
QLi5 Therapeutics GmbH
82%
Aurinia Pharmaceuticals Inc.
76%

iProtics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedOct 10, 2024
GrantMar 20, 2024
AcceleratorSep 9, 2022

Key People

Founding team and executive leadership

Elmer Maurits

CEO Co-founder

Founding Team

iProtics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 10, 2024

    $380K round led by uniiq

  • Mar 20, 2024

    $220K grant from Netherlands Organization for Scientific Research.

iProtics Filings

Explore SEC and related filing metadata, where available.

iProtics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about iProtics's valuation, stock price, and market status.

Is iProtics a public or private company?

iProtics is a private company.

What is the current stock price of iProtics?

iProtics is a private company with no public stock price. No recent secondary market data is available.

How much is iProtics worth (valuation)?

Valuation information for iProtics is not publicly available.

Can I buy iProtics stock?

iProtics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was iProtics's last funding round?

iProtics's most recent funding round was Seed on October 10, 2024.

Who are the main investors in iProtics?

Key investors in iProtics include Libertatis Ergo Holding, Netherlands Organization for Scientific Research, Life Sciences @ Work Venture Challenge.

Will iProtics IPO soon?

No public IPO plans have been announced for iProtics.

How can I track iProtics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor iProtics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLeiden
Employee Range2
Year Founded2024
Last FundingOct 10, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?